Orange Book Blog

American Conference Institute will be holding their 8th annual "Paragraph IV Disputes" conference on April 28-29 in New York.  Highlights of the conference include a district court judges panel, a magistrate judges panel, and an FTC keynote address.  Here is the complete agenda:

• On the 30th Anniversary of the Drug Price Competition and Patent Term Restoration Act: Understanding Hatch-Waxman's Transformative Impact on the Pharmaceutical Industry
• Assessing Pharmaceutical Patent Sustainability and Vulnerability: Strategies and Considerations for Brand Names and Generics in Anticipating, Identifying and Determining Which Patents Will be Ripe for Challenges of Invalidity and Non-Infringement
• Use of IPR and Other PTO Proceedings in a Paragraph IV Challenge: Strategies for Brand Names and Generics in Navigating PTO Proceedings in ANDA Litigation
• The Gauntlet Rethrown: The Paragraph IV Certification and Notice Letter
• Of Prior Art and Double Patenting: Exploring the Dichotomy Between the Federal Circuit and PTO on Obviousness Findings and Potential Impact of the Goodlatte Bill on Obviousness-Type Double Patenting
• Let the Games Begin: Advanced Strategies for Drafting and Perfecting Pleadings and Effectively Using Dispositive Motions in Paragraph IV Disputes
• Working With Local Counsel and Within Local Rules: Magistrate and Local Counsel Roundtable
• A View From the Bench: District Court Judges Panel
• Claim Construction and Markman Hearings: Standards, Jurisprudential Splits and Strategies for Paragraph IV Litigation
• FTC Keynote: Reverse Payment Settlements and Other Antitrust Concerns Impacting Paragraph IV Litigation in the Wake of Actavis
• Perils of the Safe Harbor: Understanding How the Resetting of the Boundaries of 271(e)(1) in the Aftermath of Classen and Momenta is Impacting Paragraph IV Litigation Strategies
• In the Limelight: Strategies and Theories of Inducement, Contributory, and Divided Infringement in Paragraph IV Litigation Concerning Method of Treatment Patents
• Assessing GDUFA Implementation and Additional Regulatory Developments of FDA Which Impact Paragraph IV Litigation
• Looking Beyond 180 Days: New Exclusivity Challenges for Brand Names and Generics and Related Implications for Paragraph IV Challenges
• A Pros and Cons Analysis of Launching At Risk and Survey of New Developments in Seeking Injunctive Relief and Damages
• Ethical Considerations for Paragraph IV Matters Before the PTO and District Courts: Inequitable Conduct and More

In addition to the main conference, ACI is offering a post-conference workshop on pharmaceutical patent settlements.

Orange Book Blog readers can receive discounted registration with code OBB200.  For more information or to register, please visit the conference website.